The American Cancer Society tracks survival rates for 22 types of localized cancer, including the most common in the US: prostate (100%), skin (99.6% five-year survival rate), breast (99.3%), lung (65 ...

Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early ...

Swiss pharma giant Roche today released financial results for the first nine months of 2025, showing that group sales grew by ...

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue ® , a biosimilar to Herceptin ® ...

A Fermanagh woman says a routine breast cancer screening at the Lakeland Forum may have saved her life, after it revealed a tumour she would ...

Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of ...

Enhertu significantly improved IDFS compared to Kadcyla, with a 53% risk reduction in invasive disease or death in high-risk, ...

Swiss pharma giant Roche Holding AG RHHBY reported sales of CHF 14.9 billion for the third quarter of 2025, up 6% year over ...

For the first nine months of 2025, Roche’s overall sales grew 7% at constant currencies to 45.9 billion Swiss francs (nearly ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...

Listening to stories of other breast cancer survivors gave Vanessa Pontes hope for her own treatment and future ...